US 2025/0145987 A1Published application

Antibodies that Bind CD3 Epsilon

AssigneeTwist Bioscience Corporation

InventorsAaron Sato, Pankaj Garg, Qiang Liu, Tom Yuan

Life of this patent

Estimating the term…

Abstract

Provided herein are methods and compositions relating to variant nucleic acid libraries encoding for antibodies including single domain antibodies. Libraries generated using methods described herein have improved characteristics including improved binding affinity. Libraries described herein include variegated libraries comprising nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence. Further described herein are protein libraries generated when the nucleic acid libraries are translated. Further described herein are cell libraries expressing variegated nucleic acid libraries described herein.

Claims10

Dependent claims

1-51. (canceled)

An antibody or antibody fragment that binds to TIGIT, wherein the antibody or antibody fragment comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein:

a. the VH comprises an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:
84, and wherein the VL comprises an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:
101;
b. the VH comprises an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:
85, and wherein the VL comprises an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:
102;
c. the VH comprises an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:
86, and wherein the VL comprises an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:
103;
d. the VH comprises an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:
87, and wherein the VL comprises an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:
104;
e. the VH comprises an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:
88, and wherein the VL comprises an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:
105;
f. the VH comprises an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:
89, and wherein the VL comprises an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:
106;
g. the VH comprises an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:
90, and wherein the VL comprises an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:
107;
h. the VH comprises an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:
91, and wherein the VL comprises an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:
108;
i. the VH comprises an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:
92, and wherein the VL comprises an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:
109;
j. the VH comprises an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:
93, and wherein the VL comprises an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:
110;
k. the VH comprises an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:
94, and wherein the VL comprises an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:
111;
l. the VH comprises an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:
95, and wherein the VL comprises an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:
112;
m. the VH comprises an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:
96, and wherein the VL comprises an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:
113;
n. the VH comprises an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:
97, and wherein the VL comprises an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:
114;
o. VH comprises an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:
98, and wherein the VL comprises an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:
115;
p. VH comprises an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:
99, and wherein the VL comprises an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:
116;
or
q. VH comprises an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:
100, and wherein the VL comprises an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:
117.

49 more elements

Dependencies are inferred from the claim text.

Facts

Application: 18/932,757Filed 31 Oct 2024
Priority: 23 Sep 2019
Published: 8 May 2025
Term ends: Not estimatedThe source records don’t support an estimate.

Classification24 codes

C12N 15/1027
Mutagenizing nucleic acids: by DNA shuffling, e.g. RSR, STEP, RPR
C12N 15/1068
Isolating an individual clone by screening libraries: template mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated…
C07K 16/005
Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies: constructed by phage libraries
C07K 16/2803
Against receptors, cell surface antigens or cell surface determinants: against the immunoglobulin superfamily

Family

Application62/904,620Us provisional application · filed 23 Sep 2019
Application62/935,603Us provisional application · filed 14 Nov 2019
Application62/945,761Us provisional application · filed 9 Dec 2019
Application17/030,232Division · filed 23 Sep 2020
Application18/932,757Division
US 12,173,282 B2Related patent
US 2021/0102195 A1Published application
US 2025/0145987 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results